Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1385369 | 0.83 | GRM4 (0.41) | KEAP1NFE2L2ALDH1A1MAPTMAPK1 | |
| SCHEMBL2324843 | 0.77 | MEN1 (0.40) | ALDH1A1 | |
| SCHEMBL1386437 | 0.77 | C1S (0.41) | C1SALDH1A1LMNAPKMPOLB | |
| SCHEMBL2327315 | 0.76 | GRM4 (0.39) | KEAP1NFE2L2ALDH1A1MAPTMAPK1 | |
| SCHEMBL12203848 | 0.66 | ALDH1A1 (0.51) | ALDH1A1LMNAPKMPOLBMAPT | |
| SCHEMBL4885646 | 0.65 | ALDH1A1 (0.39) | KEAP1NFE2L2ALDH1A1LMNAPKM | |
| SCHEMBL23399438 | 0.65 | NR4A3 (0.53) | ALDH1A1LMNAPKMPOLBMAPT | |
| SCHEMBL2123401 | 0.65 | NR4A3 (0.49) | ALDH1A1LMNAPKMPOLBMAPT | |
| SCHEMBL773204 | 0.64 | NR4A3 (0.78) | KEAP1NFE2L2ALDH1A1LMNAPOLB | |
| SCHEMBL13593554 | 0.63 | ALDH1A1 (0.63) | ALDH1A1LMNAPOLBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4787321-B2 | — | — | 2011-10-05 | — | — | JP | claimed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | claimed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | claimed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | claimed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | claimed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | KEAP1 724/4885NFE2L2 1398/4885C1S 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.